[SCHEDULE 13G/A] Bicara Therapeutics Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

SCHEDULE 13G/A

Rhea-AI Filing Summary

Analyzing...

07/17/2025 - 11:08 AM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Bicara Therapeutics

NASDAQ:BCAX

BCAX Rankings

#3897 Ranked by Market Cap

N/A Ranked by Dividends

BCAX Latest News

Jun 3, 2025

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 1, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

May 22, 2025

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

May 13, 2025

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

BCAX Latest SEC Filings

Jul 17, 2025

[SCHEDULE 13G] Bicara Therapeutics Inc. SEC Filing

Jun 18, 2025

[Form 4] Bicara Therapeutics Inc. Insider Trading Activity

BCAX Stock Data

Market Cap 541.00M

Float 43.93M

Insiders Ownership 0.43%

Institutions Ownership 86.05%

Short Percent 10.31%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City CAMBRIDGE